Mercados españoles abiertos en 3 hrs 42 min

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Precio demorado. Divisa en USD
Añadir a la lista de favoritos
13,25+0,24 (+1,84%)
Al cierre: 04:00PM EDT
13,30 +0,05 (+0,38%)
Después del cierre: 07:36PM EDT

Teva Pharmaceutical Industries Limited

124 Dvora HaNevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com

Sector(es)Healthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo35.001

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Richard D. FrancisPresident, CEO & Director6,71MN/A1968
Mr. Eliyahu Sharon KalifExecutive VP & CFO1,94MN/A1974
Mr. Eric DrapeExecutive Vice President of Global Operations2,25MN/A1962
Mr. Mark SabagExecutive Vice President of International Markets Commercial1,73MN/A1971
Mr. Richard Gordon DaniellExecutive Vice President of European Commercial1,66MN/A1967
Mr. Amir WeissSenior VP & Chief Accounting OfficerN/AN/A1977
Ran MeirHead of Investor RelationsN/AN/AN/A
Kathleen VeitSenior Vice President, Global Compliance & Ethics OfficerN/AN/AN/A
Mr. David R. Mcavoy J.D.Executive VP & Chief Legal OfficerN/AN/A1963
Ms. Vikki ConwayActing Head of Global Human ResourcesN/AN/A1972
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Gobierno corporativo

El ISS Governance QualityScore de Teva Pharmaceutical Industries Limited, a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 9; Tablero: 3; Derechos de los accionistas: 5; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.